Maze Therapeutics is a groundbreaking brand that harnesses the power of human genetics to revolutionize patient lives. With their cutting-edge approach, they aim to decode the mysteries of the genetic drivers behind various serious diseases. Their mission is to develop genetically informed therapies for common conditions like chronic kidney disease, leveraging their Compass Platform™ that combines variant functionalization with advanced data science methods.

Maze Therapeutics is actively building a diverse portfolio of both wholly owned and partnered programs. Their robust research and development capabilities enable them to advance a pipeline of novel precision medicines. Excitingly, Maze Therapeutics recently announced an exclusive worldwide license agreement with Sanofi for MZE001, an oral substrate reduction therapy designed to treat Pompe Disease.

They have also released new clinical data and positive Phase 1 results from their first-in-human trial, further supporting MZE001 as a potential oral treatment for Pompe Disease. With their commitment to groundbreaking science and transformative therapies, Maze Therapeutics is spearheading the future of healthcare. Contact them at info@mazetx.

com or visit their headquarters at 171 Oyster Point Blvd, Suite 300, South San Francisco